Trial Profile

A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety and Tolerability of Liposomal Treprostinil Inhalation Suspension (L606) in Subjects With Pulmonary Arterial Hypertension or Pulmonary Hypertension Associated With Interstitial Lung Disease

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 12 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Jan 2026 According to a Liquidia Technologies media release, the data from this trial will be presented at the Pulmonary Vascular Research Institute 2026 Annual Congress be held January 28 through February 1, 2026, in Dublin, Ireland.
15 Dec 2025 Planned End Date changed from 31 Jul 2025 to 31 Mar 2031.
15 Dec 2025 Actual primary completion date changed from 30 Jun 2024 to 20 Mar 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com